ArticleVaccines2021

Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial.

Sybil Tasker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.